Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Wen-Ying Lee 1, 2 , Wai-Theng Lee 3 , Chia-Hsiung Cheng 3, 4 , Ku-Chung Chen 3, 4 , Chih-Ming Chou 3, 4 , Chu-Hung Chung 5 , Min-Siou Sun 5 , Hung-Wei Cheng 3 , Meng-Ni Ho 3 , Cheng-Wei Lin 3, 4 1 Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan 2 Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 3 Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 4 Graduate Institute of Medical Sciences, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 5 Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan Correspondence to: Cheng-Wei Lin, e-mail: cwlin@tmu.edu.tw Keywords: chlorpromazine, drug reposition, p53, apoptosis, SIRT1 Received: May 04, 2015 Accepted: August 24, 2015 Published: September 05, 2015 ABSTRACT Investigating existing drugs for repositioning can enable overcoming bottlenecks in the drug development process. Here, we investigated the effect and molecular mechanism of the antipsychotic drug chlorpromazine (CPZ) and identified its potential for treating colorectal cancer (CRC). Human CRC cell lines harboring different p53 statuses were used to investigate the inhibitory mechanism of CPZ. CPZ effectively inhibited tumor growth and induced apoptosis in CRC cells in a p53-dependent manner. Activation of c-jun N-terminal kinase (JNK) was crucial for CPZ-induced p53 expression and the subsequent induction of tumor apoptosis. Induction of p53 acetylation at lysine382 was involved in CPZ-mediated tumor apoptosis, and this induction was attenuated by sirtuin 1 (SIRT1), a class III histone deacetylase. By contrast, knocking down SIRT1 sensitized tumor cells to CPZ treatment. Moreover, CPZ induced the degradation of SIRT1 protein participating downstream of JNK, and JNK suppression abrogated CPZ-mediated SIRT1 downregulation. Clinical analysis revealed a significant association between high SIRT1 expression and poor outcome in CRC patients. These data suggest that SIRT1 is an attractive therapeutic target for CRC and that CPZ is a potential repositioned drug for treating CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“Approximately 75% of TP53 gene mutations are point mutations, which lead to amino acid substitutions and result in the inhibition of normal p53 function and loss of suppressor function [2].”
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Acetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570 · cited 1×
“By contrast, deacetylation of p53 by deacetylases such as histone deacetylase (HDAC) and sirtuin 1 (SIRT1) destabilizes it and facilitates MDM2-mediated protein degradation [6, 7].”
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Gao, Z., Zhang, J., Kheterpal, I., Kennedy, N., Davis, R. J., & Ye, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228874 · Cited by 187 · cited 1×
“com/oncotarget by insulin treatment promotes SIRT1 degradation and inactivation in hepatocytes [48].”
Cited by
Sirtuin functions and modulation: from chemistry to the clinic
Carafa, V., Rotili, D., Forgione, M., Cuomo, F., Serretiello, E., Hailu, G. S., Jarho, E., Lahtela-Kakkonen, M., Mai, A., & Altucci, L. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0224-3 · Cited by 387
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
“In colorectal cancer cells, chlorpromazine induces apoptosis via up-regulation of p53 (134).”
BackgroundDrug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
“The p53 protein is encoded by the TP53 gene [61].”
Lai, J.-I., Tseng, Y.-J., Chen, M.-H., Huang, C.-Y. F., & Chang, P. M.-H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561936 · Cited by 144
“There has been much active research relating to chlorpromazine and its anticancer properties, as it has been reported to suppress the Hippo pathway related YAP signaling and cancer stemness (59), suppress chemoresistant cancer growth (60, 61), epigenetic anticancer mechanisms (62), and many other abilities.”
BackgroundNew drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Metadata
- Authors
- Lee, W.-Y., Lee, W.-T., Cheng, C.-H., Chen, K.-C., Chou, C.-M., Chung, C.-H., Sun, M.-S., Cheng, H.-W., Ho, M.-N., & Lin, C.-W.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-09-05
- Volume
- 6
- Issue
- 29
- Pages
- 27580-27595
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2265260642
- Cited by
- 58
- References
- 7
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. https://app.cochat.ai/papers/10.18632/oncotarget.4768
- The paper
- Lee, W.-Y., Lee, W.-T., Cheng, C.-H., Chen, K.-C., Chou, C.-M., Chung, C.-H., Sun, M.-S., Cheng, H.-W., Ho, M.-N., & Lin, C.-W. (2015). Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. Oncotarget. https://doi.org/10.18632/oncotarget.4768
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.